Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.40+0.40 (+2.22%)
Close on Nov 18, 2026Market cap $2.94BP/E –Yield –
Denali Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Denali Therapeutics's price to sales ratio was 11.8× on Jul 31, 2024, against 38.3× a year earlier. Over the last 5 years it ranged from 6.5× to 426.7×, with a median of 28.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jul 31, 2024 | 11.8× | +3.1 |
| 2023 | Dec 29, 2023 | 8.7× | −22.4 |
| 2022 | Dec 30, 2022 | 31.1× | +15.7 |
| 2021 | Dec 31, 2021 | 15.4× | −411.3 |
| 2020 | Dec 31, 2020 | 426.7× | +415.4 |
| 2019 | Dec 31, 2019 | 11.3× | – |
See a number that looks wrong?